Stock HPHA HEIDELBERG PHARMA AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Heidelberg Pharma AG Deutsche Boerse AG

Equities

HPHA

DE000A11QVV0

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG
Other stock markets
 12:41:14 31/05/2024 pm IST 		5-day change 1st Jan Change
2.85 EUR -0.35% Intraday chart for Heidelberg Pharma AG -1.72% -21.92%
25/04 Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024 CI
23/04 Transcript : Heidelberg Pharma AG - Special Call

Valuation

Fiscal Period: November 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 62.23 161.5 177 266.5 128.6 134.7 -
Enterprise Value (EV) 1 52.35 156.7 171 266.5 128.6 134.7 134.7
P/E ratio -6.14 x -8.52 x -6.48 x -10.8 x -6.27 x -9.63 x -22.2 x
Yield - - - - - - -
Capitalization / Revenue 7.81 x 16.9 x 76.5 x 13.4 x 7.66 x 11.7 x 8.98 x
EV / Revenue 7.81 x 16.9 x 76.5 x 13.4 x 7.66 x 11.7 x 8.98 x
EV / EBITDA -6.48 x -9.2 x -7.13 x -16.2 x -6.33 x -6.09 x -12.5 x
EV / FCF -65,79,197 x -83,85,943 x -63,55,429 x - - - -
FCF Yield -0% -0% -0% - - - -
Price to Book 3.83 x 12.5 x 26.4 x - - - -
Nbr of stocks (in thousands) 28,158 31,062 34,173 46,584 46,600 46,605 -
Reference price 2 2.210 5.200 5.180 5.720 2.760 2.890 2.890
Announcement Date 19/03/20 25/03/21 24/03/22 05/03/23 25/03/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: November 2019 2020 2021 2022 2023 2024 2025
Net sales 1 7.964 9.576 2.314 19.86 16.8 11.5 15
EBITDA 1 -9.597 -17.55 -24.83 -16.42 -20.33 -22.1 -10.8
EBIT 1 -10.14 -18.28 -25.63 -17.18 -21.21 -22.6 -11.6
Operating Margin -127.36% -190.95% -1,107.81% -86.51% -126.24% -196.52% -77.33%
Earnings before Tax (EBT) -10.14 -18.28 -26.14 -17.79 -20.35 - -
Net income -10.15 -18.28 -26.14 -19.7 -20.35 - -
Net margin -127.43% -190.95% -1,129.76% -99.2% -121.1% - -
EPS 2 -0.3600 -0.6100 -0.8000 -0.5300 -0.4400 -0.3000 -0.1300
Free Cash Flow -9.458 -19.26 -27.85 - - - -
FCF margin -118.77% -201.14% -1,203.84% - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 19/03/20 25/03/21 24/03/22 05/03/23 25/03/24 - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: November 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position 9.88 4.78 5.97 - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow -9.46 -19.3 -27.9 - - - -
ROE (net income / shareholders' equity) -48.1% -125% - - - - -
ROA (Net income/ Total Assets) -37.5% - - - - - -
Assets 27.09 - - - - - -
Book Value Per Share 0.5800 0.4100 0.2000 - - - -
Cash Flow per Share - - - - - - -
Capex 0.9 1.37 1.24 - - - -
Capex / Sales 11.32% 14.29% 53.69% - - - -
Announcement Date 19/03/20 25/03/21 24/03/22 05/03/23 25/03/24 - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.89 EUR
Average target price
11.3 EUR
Spread / Average Target
+291.00%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 12TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 11TCr
BIONTECH SE Stock BioNTech SE
-4.68% 2.43TCr
ARGENX SE Stock argenx SE
-0.82% 2.2TCr
GENMAB A/S Stock Genmab A/S
-10.12% 1.82TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 1.64TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 1.56TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 1.36TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 1.23TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. HPHA Stock
  4. HPHA Stock
  5. Financials Heidelberg Pharma AG